Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALIRIFOX plus adbelimumab for first-line advanced biliary tract cancer
ChiCTR2400089696Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab, irinotecan liposome, oxaliplatin, fluorouracil and folinic acid in biliary cancer, cholangiocarcinoma (CCA) and gallbladder adenocarcinoma, sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
adebrelimabirinotecan liposomeoxaliplatinfluorouracilfolinic acid
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400089696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089696.